Targeting angiogenesis in pancreatic cancer

Rationale and pitfalls

Chery Whipple, Murray Korc

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20% of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival. Materials and methods: This review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.

Original languageEnglish (US)
Pages (from-to)901-910
Number of pages10
JournalLangenbeck's Archives of Surgery
Volume393
Issue number6
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Neoplasms
Drug Therapy
Radiotherapy
Therapeutics

Keywords

  • Angiogenesis
  • Angiogenesis inhibitors
  • Invasion
  • Metastasis
  • Pancreatic ductal adenocarcinoma (PDAC)

ASJC Scopus subject areas

  • Surgery

Cite this

Targeting angiogenesis in pancreatic cancer : Rationale and pitfalls. / Whipple, Chery; Korc, Murray.

In: Langenbeck's Archives of Surgery, Vol. 393, No. 6, 11.2008, p. 901-910.

Research output: Contribution to journalArticle

Whipple, Chery ; Korc, Murray. / Targeting angiogenesis in pancreatic cancer : Rationale and pitfalls. In: Langenbeck's Archives of Surgery. 2008 ; Vol. 393, No. 6. pp. 901-910.
@article{351b2cc152ab4b869c50a783873d3917,
title = "Targeting angiogenesis in pancreatic cancer: Rationale and pitfalls",
abstract = "Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20{\%} of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival. Materials and methods: This review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.",
keywords = "Angiogenesis, Angiogenesis inhibitors, Invasion, Metastasis, Pancreatic ductal adenocarcinoma (PDAC)",
author = "Chery Whipple and Murray Korc",
year = "2008",
month = "11",
doi = "10.1007/s00423-008-0280-z",
language = "English (US)",
volume = "393",
pages = "901--910",
journal = "Langenbeck's Archives of Surgery",
issn = "1435-2443",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Targeting angiogenesis in pancreatic cancer

T2 - Rationale and pitfalls

AU - Whipple, Chery

AU - Korc, Murray

PY - 2008/11

Y1 - 2008/11

N2 - Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20% of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival. Materials and methods: This review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.

AB - Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer responsible for over 20% of deaths due to gastrointestinal malignancies. PDAC is usually diagnosed at an advanced stage which, in part, helps to explain its high resistance to chemotherapy and radiotherapy. In addition, the cancer cells in PDAC have a high propensity to metastasize and to aberrantly express several key regulators of angiogenesis and invasion. Chemotherapy has only provided a modest impact on mean survival and often induces side effects. Targeting angiogenesis alone or in combination with other modalities should be investigated to determine if it may provide for increased survival. Materials and methods: This review summarizes the alterations in PDAC that play a critical role in angiogenesis and provides an overview of current and therapeutic strategies that may be useful for targeting angiogenesis in this malignancy.

KW - Angiogenesis

KW - Angiogenesis inhibitors

KW - Invasion

KW - Metastasis

KW - Pancreatic ductal adenocarcinoma (PDAC)

UR - http://www.scopus.com/inward/record.url?scp=53549092538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549092538&partnerID=8YFLogxK

U2 - 10.1007/s00423-008-0280-z

DO - 10.1007/s00423-008-0280-z

M3 - Article

VL - 393

SP - 901

EP - 910

JO - Langenbeck's Archives of Surgery

JF - Langenbeck's Archives of Surgery

SN - 1435-2443

IS - 6

ER -